Data gathered: June 24
AI Stock Analysis - Halozyme Therapeutics (HALO)
Analysis generated November 16, 2024. Powered by Chat GPT.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company focused on developing and commercializing oncology and drug-delivery therapies. Halozyme partners with pharmaceutical and biotechnology companies to apply its proprietary ENHANZE® technology, an enzyme-based drug delivery system, to improve the efficacy and efficiency of injectable drugs and biologics. The company’s innovative approaches and collaborations have positioned it as a key player in the drug delivery market.
Stock Alerts - Halozyme Therapeutics (HALO)
 |
Halozyme Therapeutics | May 16 Price is up by 7% in the last 24h. |
|
Halozyme Therapeutics | May 13 Price is down by -14.8% in the last 24h. |
|
Halozyme Therapeutics | May 7 Price is up by 8.6% in the last 24h. |
|
Halozyme Therapeutics | April 29 Insider Alert: Henderson Jeffrey William is selling shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Halozyme Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 12 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | 8 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,791 | Sign up | Sign up | Sign up |
| Twitter Followers | 623 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 73 | Sign up | Sign up | Sign up |
| Linkedin Employees | 462 | Sign up | Sign up | Sign up |
About Halozyme Therapeutics
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
| Price | $52.80 |
| Target Price | Sign up |
| Volume | 1,930,000 |
| Market Cap | $6.51B |
| Year Range | $42.57 - $70.14 |
| Dividend Yield | 0% |
| PE Ratio | 14.04 |
| Analyst Rating | 43% buy |
| Industry | Biotechnology |
In the news
Halozyme Therapeutics, Inc. Announces Argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating PolyneuropathyJune 20 - Finnhub |
|
 |
Janney Montgomery Scott LLC Grows Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)June 19 - ETF Daily News |
 |
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum StockJune 15 - Yahoo |
|
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $61.90 Consensus Price Target from BrokeragesJune 15 - ETF Daily News |
 |
Halozyme Therapeutics: The Waters Become MuddledJune 14 - SeekingAlpha |
|
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-TermJune 12 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 265M | 48M | 216M | 118M | 169M | 1.110 |
| Q4 '24 | 298M | 42M | 256M | 137M | 203M | 1.260 |
| Q3 '24 | 290M | 49M | 241M | 137M | 190M | 1.270 |
| Q2 '24 | 231M | 57M | 174M | 93M | 138M | 0.910 |
| Q1 '24 | 196M | 46M | 150M | 77M | 116M | 0.790 |
Insider Transactions View All
| Henderson Jeffrey William filed to sell 28,611 shares at $61. April 28 '25 |
| Henderson Jeffrey William filed to sell 28,811 shares at $60.3. April 28 '25 |
| Henderson Jeffrey William filed to sell 33,108 shares at $64.1. April 1 '25 |
| Henderson Jeffrey William filed to sell 36,816 shares at $57.9. March 3 '25 |
| Henderson Jeffrey William filed to sell 33,611 shares at $59.1. March 3 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Gil Cisneros |
Apr 8, 25 | Sell | $1K - $15K |
| Daniel S. Goldman Democrat |
Aug 13, 23 | Sell | $15K - $50K |
Read more about Halozyme Therapeutics (HALO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Halozyme Therapeutics?
The Market Cap of Halozyme Therapeutics is $6.51B.
What is Halozyme Therapeutics' PE Ratio?
As of today, Halozyme Therapeutics' PE (Price to Earnings) ratio is 14.04.
What is the current stock price of Halozyme Therapeutics?
Currently, the price of one share of Halozyme Therapeutics stock is $52.80.
How can I analyze the HALO stock price chart for investment decisions?
The HALO stock price chart above provides a comprehensive visual representation of Halozyme Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Halozyme Therapeutics shares. Our platform offers an up-to-date HALO stock price chart, along with technical data analysis and alternative data insights.
Does HALO offer dividends to its shareholders?
As of our latest update, Halozyme Therapeutics (HALO) does not offer dividends to its shareholders. Investors interested in Halozyme Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Halozyme Therapeutics?
Some of the similar stocks of Halozyme Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.